id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2017-D-5966-0014,FDA,FDA-2017-D-5966,Breakthrough Devices Program; Guidance for Industry and Food and Drug Administration Staff; Availability,Notice,Notice of Availability,2023-09-15T04:00:00Z,2023,9,2023-09-15T04:00:00Z,,2023-09-15T15:27:40Z,2023-20007,0,0,0900006485fadccd
FDA-2017-D-5966-0015,FDA,FDA-2017-D-5966,Breakthrough Devices Program Guidance for Industry and Food and Drug Administration Staff; Final Guidance,Other,Guidance,2023-09-15T04:00:00Z,2023,9,2023-09-15T04:00:00Z,,2025-11-08T10:00:17Z,,1,0,0900006485fb150e